KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $68.49 $68.49 Friday, 27th Jan 2023 GBT stock ended at $68.49. During the day the stock fluctuated 0% from a day low at $68.49 to a day high of $68.49.
90 days $68.49 $68.49
52 weeks $21.65 $73.02

Historical GLOBAL BLOOD THERAPEUTICS prices

Date Open High Low Close Volume
Feb 17, 2016 $16.39 $18.04 $16.39 $17.47 299 700
Feb 16, 2016 $15.14 $16.69 $15.14 $16.17 607 900
Feb 12, 2016 $14.52 $15.03 $14.21 $14.94 204 000
Feb 11, 2016 $13.39 $14.43 $12.89 $14.36 343 800
Feb 10, 2016 $13.14 $14.23 $12.69 $13.76 434 600
Feb 09, 2016 $14.70 $15.50 $12.85 $12.95 403 700
Feb 08, 2016 $17.32 $17.32 $14.72 $15.03 661 700
Feb 05, 2016 $19.32 $19.32 $18.35 $18.58 231 600
Feb 04, 2016 $19.37 $20.07 $18.93 $19.55 207 900
Feb 03, 2016 $19.02 $19.60 $17.71 $19.53 346 700
Feb 02, 2016 $18.85 $19.22 $18.35 $18.78 316 300
Feb 01, 2016 $18.63 $19.62 $16.99 $19.24 500 700
Jan 29, 2016 $19.25 $19.45 $18.16 $18.93 215 700
Jan 28, 2016 $19.88 $19.88 $18.50 $19.32 345 900
Jan 27, 2016 $20.94 $20.94 $19.41 $19.61 234 600
Jan 26, 2016 $19.62 $21.26 $19.47 $20.94 312 800
Jan 25, 2016 $19.48 $19.96 $19.11 $19.49 334 400
Jan 22, 2016 $19.78 $20.05 $19.04 $19.50 329 900
Jan 21, 2016 $20.26 $20.99 $19.16 $19.29 193 900
Jan 20, 2016 $19.85 $20.97 $18.40 $20.21 339 300
Jan 19, 2016 $21.74 $21.74 $19.32 $20.29 293 700
Jan 15, 2016 $21.66 $22.38 $20.38 $21.31 314 700
Jan 14, 2016 $21.10 $26.77 $21.10 $22.87 965 100
Jan 13, 2016 $23.63 $23.73 $20.43 $21.32 389 800
Jan 12, 2016 $23.44 $23.75 $22.80 $23.41 245 900
Click to get the best stock tips daily for free!

About GLOBAL BLOOD THERAPEUTICS

GLOBAL BLOOD THERAPEUTICS Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, ... GBT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT